Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging

Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload

(2014) Yilma T. Adem et al.   BIOCONJUGATE CHEMISTRY

Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation

(2013) Lourdes Castañeda et al.   CHEMICAL COMMUNICATIONS

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Antibody-drug conjugates

(2013) Alain Beck et al.   mAbs

A mild synthesis of N-functionalised bromomaleimides, thiomaleimides and bromopyridazinediones

(2013) Lourdes Castañeda et al.   TETRAHEDRON LETTERS

Homogeneous antibody fragment conjugation by disulfide bridging introduces ‘spinostics’

(2013) Felix F. Schumacher et al.   Scientific Reports

Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines

(2012) D. Scott Wilbur et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates for the Treatment of Cancer

(2012) John A. Flygare et al.   Chemical Biology & Drug Design

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

(2011) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylation

(2011) Felix F. Schumacher et al.   BIOCONJUGATE CHEMISTRY

Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis

(2011) Chris P. Ryan et al.   CHEMICAL COMMUNICATIONS

Brentuximab Vedotin (SGN-35)

(2011) J. Katz et al.   CLINICAL CANCER RESEARCH

The development of pyrrolobenzodiazepines as antitumour agents

(2011) John A Hartley   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates

(2011) Robert Y. Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Analytical methods for physicochemical characterization of antibody drug conjugates

(2011) Aditya Wakankar et al.   mAbs

Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes

(2010) Aditya A. Wakankar et al.   BIOCONJUGATE CHEMISTRY

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Chemoenzymatic methods for site-specific protein modification

(2010) David Rabuka   CURRENT OPINION IN CHEMICAL BIOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate

(2008) Svetlana O. Doronina et al.   BIOCONJUGATE CHEMISTRY

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY